tradingkey.logo

Sanara Medtech Inc

SMTI
View Detailed Chart
27.850USD
-0.020-0.07%
Market hours ETQuotes delayed by 15 min
247.97MMarket Cap
LossP/E TTM

Sanara Medtech Inc

27.850
-0.020-0.07%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.07%

5 Days

-3.33%

1 Month

-10.91%

6 Months

-12.56%

Year to Date

-16.11%

1 Year

-20.81%

View Detailed Chart

TradingKey Stock Score of Sanara Medtech Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sanara Medtech Inc's Score

Industry at a Glance

Industry Ranking
86 / 159
Overall Ranking
237 / 4615
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
50.000
Target Price
+81.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sanara Medtech Inc Highlights

StrengthsRisks
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 89.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 86.67M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 86.67M.
Overvalued
The company’s latest PE is -24.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.10M shares, decreasing 4.41% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 378.00 shares of this stock.

Sanara Medtech Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Sanara Medtech Inc Info

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Ticker SymbolSMTI
CompanySanara Medtech Inc
CEOMr. Suresh V. (Sam) Muppalla
Websitehttps://sanaramedtech.com/
KeyAI